Oxyberberine, a gut microbiota‐mediated oxidative metabolite of berberine, inhibits the aberrant phosphorylation of IRS‐1 and promotes phosphorylation levels of its downstream, thereby improving insulin signaling to alleviate NAFLD.233. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.